All In MedTech

Device Trial Radar · NCT07287111

Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound

Multi-Reader Multi-Case, Cross-Over, Retrospective Study to Evaluate the Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 797 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

797

Actual

Start

Aug 30, 2025

Primary completion

Oct 7, 2025

Study completion Jul 28, 2026

Sponsor

Lead sponsor
BeamWorks Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 17, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
Female only, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a retrospective, fully-crossed, multi-reader, multi-case (MRMC) study to evaluate the effectiveness of 'CadAI-B Dx' (CadAI-B) for decision support in breast ultrasound. The study compares the diagnostic performance of readers interpreting breast ultrasound images with and without the aid of CadAI-B. A total of 797 patient cases will be included, comprising 350 cases with a confirmed diagnosis of malignancy and 447 cases with a confirmed benign diagnosis. Sixteen readers will participate in the study to evaluate the device.

Conditions

  • Breast Cancer
  • Breast Neoplasms

Interventions

  • CadAI-B DxDevice

    CadAI-B Dx is a Software as a Medical Device (SaMD) designed to assist physicians by providing Computer-Aided Detection (CADe) and Diagnosis (CADx) capabilities in breast ultrasound interpretation. The software automatically processes the image to identify suspicious regions (Lesion Detection) and provides a quantitative malignancy score (CadAI-Score) mapped to a corresponding BI-RADS Category. It also analyzes lesion size and BI-RADS lexicon descriptors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Localization Receiver Operating Characteristic (LROC) Curve (AULROC)Time frame: Through study completion, approximately 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yonsei University Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.